Study on the possible hepatoprotive effect of certain drugs against ischemia/reperfusion liver injury in rats /
Abdallah Mohammed Said Ahmed Gendy
Study on the possible hepatoprotive effect of certain drugs against ischemia/reperfusion liver injury in rats / التأثير الكبدى الوقائى المحتمل لبعض الأدوية ضد الدم فى كبد الجرزان المتبوع بإعادة التروية Abdallah Mohammed Said Ahmed Gendy ; Supervised Hanan Salaheldin Elabhar , Rania Mohsen Abdelsalam - Cairo : Abdallah Mohammed Said Ahmed Gendy , 2014 - 167 P. : charts ; 25cm
Thesis (M.Sc.) - Cairo University - Faculty of Pharmacy - Department of Pharmacology and Toxicology
Cilostazol is an antiplatelet that acts by inhibiting phosphodiesterase-3 and that was proven to be effective in models of ischemia/reperfusion (I/R) injury; however, its possible role in hepatic 1/R remains indistinct, which is the aim of the current work. cilostazol potential effect was compared to known ani-ischemic drug trimetazidine, which is used as an antianginal drug and that protects heart and liver against 1/R. to fulfill the goal, rats were randomized into sham, 1/R, cilostazol (60mg/Kg, p.o) and trimetazidine (20mg/kg, p.o) groups
Cilostazol Hepatic ischemia Trimetazidine
Study on the possible hepatoprotive effect of certain drugs against ischemia/reperfusion liver injury in rats / التأثير الكبدى الوقائى المحتمل لبعض الأدوية ضد الدم فى كبد الجرزان المتبوع بإعادة التروية Abdallah Mohammed Said Ahmed Gendy ; Supervised Hanan Salaheldin Elabhar , Rania Mohsen Abdelsalam - Cairo : Abdallah Mohammed Said Ahmed Gendy , 2014 - 167 P. : charts ; 25cm
Thesis (M.Sc.) - Cairo University - Faculty of Pharmacy - Department of Pharmacology and Toxicology
Cilostazol is an antiplatelet that acts by inhibiting phosphodiesterase-3 and that was proven to be effective in models of ischemia/reperfusion (I/R) injury; however, its possible role in hepatic 1/R remains indistinct, which is the aim of the current work. cilostazol potential effect was compared to known ani-ischemic drug trimetazidine, which is used as an antianginal drug and that protects heart and liver against 1/R. to fulfill the goal, rats were randomized into sham, 1/R, cilostazol (60mg/Kg, p.o) and trimetazidine (20mg/kg, p.o) groups
Cilostazol Hepatic ischemia Trimetazidine